 clinic evalu interferon malign melanoma evalu interferon treatment malign melanoma treatment advanc diseas interferon sole agent combin agent studi valu interferon adjuv therapi high-risk primari melanoma patient necessari result date human interferon alpha low respons rate sole agent combin cimetidin respons rate recombin alpha interferon respons advanc melanoma combin cimetidin respons rate recombin alpha interferon combin interferon cimetidin monoclon antibodi cytotox small improv respons rate dtic recombin interferon object respons rate low toxic mainten qualiti life random trial dtic sole agent combin treatment signific find